跳至主要内容
临床试验/NCT01455740
NCT01455740已完成不适用

A Commitment Device for Medication Adherence Among HIV Patients

National Bureau of Economic Research, Inc.2 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2011年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
110
试验地点
2
主要终点
Virologic Suppression (pVL =< 200 copies/mL) at Fifth Study Visit

研究概览

简要总结

We used a randomized trial design combined with a comparison to a non-randomized control group to study patients on appropriate antiretroviral therapy (ART) having virologic failure within a publicly-funded HIV clinic serving Atlanta, GA.

详细描述

This study demonstrated the feasibility of using commitment contracts in HIV care. Many previous interventions have produced statistically significant effects on ART adherence that do not persist after the intervention ends. A notable feature of our study is that after the incentives for ART adherence and provider visits were removed, participants who had been offered a commitment contract for ART adherence were more likely to achieve virologic suppression relative to individuals who had been assigned a conditional cash transfer for provider visits and relative to individuals who had been assigned the standard of care, although the difference was only statistically significant in the latter comparison. There were differences in the prevalence of missing outcomes across groups, but these differences were not statistically significant for the unanticipated post-incentive visit and therefore were unlikely to be the explanation for the results. Thus, financial rewards coupled with individual choice can increase engagement in healthy behaviors after incentives are removed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Attended the Grady Health System Infectious Disease Program (IDP)
  • Most recent HIV-1 plasma RNA viral load (pVL) > 200 copies/mL; this value must have been measured within the prior 18 months and at least 6 months after starting the current ART regimen
  • English-speaking

排除标准

  • Using pillboxes
  • Were planning to relocate
  • Were enrolled in another trial

结局指标

主要结局

Virologic Suppression (pVL =< 200 copies/mL) at Fifth Study Visit

时间窗: 12 months (median)

次要结局

  • Virologic Suppression (pVL =< 200 copies/mL) at Unanticipated Sixth Study Visit(15 months (median))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验